Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Inflammation01:38

Inflammation

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunopathophysiology of immune checkpoint inhibitor-related pneumonitis: insights from multi-omics and immune profiling.

Immunological medicineยท2026
Same author

Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).

RMD openยท2026
Same author

Lenvatinib Combined with PD-1 Blockade Therapy Benefits Gastric Cancers through Immunosuppressive Macrophage Modulation.

Cancer immunology researchยท2026
Same author

Distinct fibrosis-associated macrophage subsets coordinate iron metabolism in pulmonary fibrosis.

International immunologyยท2026
Same author

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.

Respiratory medicineยท2026
Same author

Subset binding enables detection of multimodal patient subgroup patterns and drug target discovery in idiopathic pulmonary fibrosis.

Briefings in bioinformaticsยท2026

Related Experiment Video

Updated: May 7, 2026

Depletion and Reconstitution of Macrophages in Mice
08:50

Depletion and Reconstitution of Macrophages in Mice

Published on: August 1, 2012

Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophages.

Yingji Jin1, Isao Tachibana, Yoshito Takeda

  • 1Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Plos One
|September 17, 2013
PubMed
Summary

Statins increase levels of tetraspanins CD9 and CD81, crucial for reducing lung inflammation. These drugs protect against inflammatory lung diseases by upregulating CD9 in macrophages.

More Related Videos

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Related Experiment Videos

Last Updated: May 7, 2026

Depletion and Reconstitution of Macrophages in Mice
08:50

Depletion and Reconstitution of Macrophages in Mice

Published on: August 1, 2012

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Tetraspanins CD9 and CD81 are involved in inflammatory lung diseases like COPD.
  • Reduced levels of CD9 and CD81 may contribute to disease progression.

Purpose of the Study:

  • To identify agents that increase CD9 and CD81 levels.
  • To investigate the anti-inflammatory mechanisms of statins involving tetraspanins.

Main Methods:

  • Screened 1,165 drugs for their ability to upregulate CD9 and CD81 in macrophages.
  • Utilized in vitro (macrophages) and in vivo (mice) models, including CD9 knockout models.
  • Investigated the effect of statins on LPS-induced inflammatory responses and CD14 localization.

Main Results:

  • Statins, particularly lipophilic ones like fluvastatin and simvastatin, upregulate CD9 and CD81 in macrophages.
  • Statins reversed LPS-induced downregulation of CD9/CD81, reducing inflammatory mediator production and cell spreading.
  • Anti-inflammatory effects were CD9-dependent, observed in wild-type but not CD9 knockout models.
  • Statins promoted reverse transfer of CD14 from lipid rafts to CD9 microdomains, inhibiting LPS receptor formation.
  • Upregulation of CD9/CD81 by statins involved blockade of GTPase geranylgeranylation in the mevalonate pathway.

Conclusions:

  • Tetraspanin CD9 acts as a negative regulator in lung inflammation.
  • Statins exert anti-inflammatory effects by upregulating CD9 in macrophages, offering a potential therapeutic strategy for inflammatory lung diseases.